FDA Approval Update for Omeprazole ANDA207740 by Dr. Reddy's
Reddy's has submitted an Abbreviated New Drug Application (ANDA) for Omeprazole, currently under review.
Published: July 11, 2026
Updated: July 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Gastroenterology / Proton Pump Inhibitor
Asset: Omeprazole
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Omeprazole
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's review of Dr. Reddy's ANDA for Omeprazole signals increased competition in the generic market for this proton pump inhibitor. This could lead to pricing pressures and shifts in market share that require strategic adjustments from existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's decision timeline and any subsequent market entry by Dr.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.